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Abstract
Background: Cryptococcal meningitis (CM) is the most 
common severe life threatening fungal infection in AIDS 
patients. It is an important cause of morbidity and 
mortality. There is paucity of data on the prevalence of CM 
in Nigeria.
 We aimed to determine the frequency of CM, the clinical 
presentation and immunological profile.
Methods: A cross sectional study was carried out at the 
Jos University Teaching Hospital (JUTH), A total of 100 
HIV-1 infected patients suspected of having meningitis or 
meningoencephalitis were subjected to cerebrospinal 
fluid (CSF) analysis (including Indian ink preparation and 
fungal culture by conventional methods) and CD4 count 
was determined using flow cytometry (count bit Y-R 1004 
Partec Muster Germany).
Results: The freguency of CM was 36% in our cohort. The 
commonest clinical presentation included headache 
(100.0%), neck stiffness (77.8%), fever (72.0%), vomiting 
(55.6%), personality changes (55.6%), photophobia 
(27.8%) and convulsions (27.8%). The mean duration of 
symptoms was 24 ±22 days with a median of 17 days. The 
3
mean CD4 count was 89±60 cells/mm  with a median of 
382 cells/mm .
Conclusion: The high prevalence of CM and the 
associated severe immunosuppression underscores the 
importance of early diagnosis of HIV infection which may 
reduce the incidence of CM. There is the urgent need for 
access to Amphotericin B and fluconazole in resource 
constrained settings in addition to a wide access to 
HAART.
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Introduction 
Cryptococcal meningitis in Acquired Immune deficiency 
Syndrome (AIDS) is an important infection described as 
AIDS defining because it's presence is highly suggestive 
of an underlying severe immune deficiency. It is caused by 
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Cryptococcus neoformans which is an encapsulated 
yeast-like fungus. It is an important cause of morbidity 
and mortality in patients with AIDS and is widely 
considered as the most common life-threatening AIDS 
1,2,3related fungal infection .
Worldwide, 33.2million people are infected with HIV, out 
of which 22.5million (68%) live in Africa. In Nigeria there 
are an estimated 2.9million adults and children living 
4with HIV /AIDS . Cryptococcal infection in AIDS is 
always associated with profound immunodeficiency 
with CD4 T cells count almost invariably less than 
5
100cells/ml . Most HIV/AIDS patients in Sub-Saharan 
Africa present with severe immunosuppression which is 
largely due to poor access to care and treatment. In 
Nigeria only 15% of persons with HIV/AIDS who need 
4. antiretroviral therapy are currently on treatment. 
In the USA approximately 7-15% of patients with AIDS 
6develop cryptococcal infection . In 1993 the US Center 
for Disease Control and Prevention (CDC) reported that 
6% of 274,150 patients with AIDS developed 
cryptococcal diseases. Furthermore, patients with AIDS 
associated cryptococcal infection now account for 80-
6
90% of all patients with cryptococcal diseases .
Sub-Saharan Africa carries the largest burden of 
Cryptococcal diseases with 15-30% of all patients with 
AIDS in this sub region developing cryptococcal 
7
diseases . However higher figures have been observed 
in some countries with a high prevalence of HIV/AIDS. 
In a report by Mossa et al, 88% of AIDS patients in 
Zimbabwe had Cryptococcal infection as their AIDS 
defining illness while in South Africa, 84% of patients 
with AIDS have Cryptococcal infection as their AIDS 
8.  defining illness The prevalence of Cryptococcal 
infection in Nigeria is unknown due to lack of accessible 
data. 
Sub-acute meningitis or meningo-encephalitis has been 
reported as manifestation of Cryptococcal infection in 
70-90% of AIDS patients, making it the most common 
manifestation of Cryptococcal infection in AIDS 
1, 9, 10patients . Most of these patients (75%) present with 
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fever, malaise and headache, and are generally 
11symptomatic for 2-4 weeks before presentation . 
Overt meningeal symptoms and signs such as neck 
stiffness or photophobia are uncommon and are 
12. 
observed in only about 25% of patients Consequently all 
patients suspected of having Cryptococcal infection must 
be evaluated for meningeal involvement. Nausea and 
vomiting occur in about 40% of patients and about 30% of 
p a t i e n t s  h a v e  s y m p t o m s  c o m p a t i b l e  w i t h  
encephalopathy, such as lethargy, altered mentation, 
personality changes and memory loss. Focal neurologic 
signs or seizures are unusual and occur in about 10% of 
12
these patients .
Cryptococcoma (large cryptococcal granuloma within the 
brain) is rare in AIDS patients. Abnormalities in brain 
imaging such as computed tomography scans or 
magnetic resonance imaging are seen in up to 20% of 
patients. 
Because of the limited health resources in our 
environment and consequent lack of diagnostic facilities, 
there are few studies on the frequency and clinical 
presentation of Cryptococcal meningitis in AIDS patients 
in Nigeria. This study was aimed at evaluating the 
frequency and describing the clinical presentation of 
cryptococcal meningitis in HIV infected patients in Jos 
University Teaching Hospital.
Materials and Methods. 
A cross sectional study was carried out at the Jos 
University Teaching Hospital (JUTH), which is a tertiary 
referral centre and one of the foremost site of the free 
Antiretroviral treatment programme of the Nigerian 
government and PEPFAR Harvard. A total of 100 
confirmed HIV-1 infected patients suspected of having 
meningitis or meningoencephalitis were subjected to 
cerebrospinal fluid (CSF) analysis (including Indian ink 
preparation and fungal culture by conventional methods) 
and CD4 count was determined using flow cytometry 
(count bit Y-R 1004 Partec Muster Germany).
Results
One hundred HIV-1 infected patients with features of 
meningitis or meningoencephalitis were studied. There 
were 34 males and 66 females. The frequecy of CM was 
36% in our cohort.  The mean age of the patients with 
Cryptococcal meningitis was 35.61±7.89 years; it ranged 
between 21.00 to 51.00years. The largest population of 
the patients is in the age group 31-40years (44%). The 
commonest clinical presentation included headache 
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(100.0%), neck stiffness (77.8%), fever (72.0%), 
vomiting (55.6%), personality changes (55.6%), 
photophobia (27.8%) and convulsions (27.8%). The 
mean duration of symptoms was 24 ±22 days with a 
median of 17 days. Persistent headache of more than 
fourteen days was reported in 61% of patients with CM. 
3
The mean CD4 count was 89±60 cells/mm  with a 
3median of 82 cells/mm .
             
CLINICAL FEATURES OF THE PATIENTS
CM  Cryptococcal Meningitis
 Variable  CM Positive 







 Sex     
Male  12 (33.3) 22 (34.4) 34 
Female  24 (66.7) 42 (65.6) 66 
Age Group     
21-30 12(33.3)  22(34.4) 34 
31-40 16(44.4) 28(43.8) 44 
41-50 6(16.7) 12(18.8) 18 
51-60 2(5.6) 2(3.1) 04 
Occupation     
Civil Servant  6 (16.7) 22 (33.4) 28 
Self Employed  20 (55.6) 26 (40.6) 46 
Student  6 (16.6) 8 (12.5) 14 
Unemployed  4(11.1) 8 (12.5) 12 
Marital Status     
Divorced  0 (00.0) 4 (6.3) 04 
Married  18 (50.0) 30 (46.9) 48 
Single  12 (33.3) 18 (28.1) 30 




Cryptococcal meningitis is the most common life 
threatening fungal infection in patients with AIDS. The 
frequency of cryptococcal meningitis has been on the 
increase since the discovery of HIV but there's been a halt 
of this trend with the introduction of Highly Active 
Antiretroviral Therapy (HAART). However in countries 
where patients have a poor access to HAART, the 
Frequency of Cryptococcal meningitis is still high. 
The study showed a frequency of 36% for Cryptococcal 
meningitis among HIV/AIDS patients in JUTH presenting 
with meningitic features. Similar results were observed by 
Bekondi et al, in a hospital study in Bangui, where they 
reported a frequency of 39.1% and Cryptococcal 
meningitis was noted as the commonest cause of 
meningitis in HIV infected patients with meningitic 
13
symptoms . In another study in Zimbabwe, Halim et al 
found that 45% of patients with meningitic features had 
Cryptococcal meningitis and it was also the most 
14
common form of meningitis . In Bamako, Mali, a 
15frequency of 30.9% was reported by Oumar AA et al 
This high frequency of Cryptococcal meningitis may be 
due to the fact that most of our patients in JUTH sought 
medical attention at advanced stage of the disease 
because a large proportion of them were not on HAART or 
had failed antiretroviral therapy.   
In countries with a fairly wider access to antiretroviral 
drugs and a better care seeking attitude, there have been 
reports of lower frequency. In South Africa, Bergeman et 
16
al reported a frequency of 13% . Another study by Jowi 
and co-workers in a hospital in Nairobi found 
Cryptococcal meningitis in 22% of HIV/AIDS patients with 
17
neurological complications .  Other studies done in 
South America showed frequencies between 20.3 - 
18,19,20
29.4% .  
The age at presentation of patients with cryptococcal 
meningitis was at a median age of 35.5 years and two 
thirds of the patients were females. Similar findings was 
observed in the age presentation of patients, by Melaku et 
al in a study in Ethiopia with a median age of 35 years, 
58.
however, a male predominance was noted (65.6%)  
Millogo and colleagues also found a median age of 34.25 
 years in Burkina Faso, and a male preponderance (66%)
21. Similar findings were also found in studies conducted in 
22, 19
Malawi and Argentina . 
The median age of the patients fell within the age bracket 
of 15 and 49 which is the age bracket worst affected by 
4HIV infection worldwide . The higher female 
preponderance in the present study could be explained 
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by the higher number of female patients presenting for 
care in our hospital. Unpublished audit in our clinic data 
shows that females make up 66.5% of the total number 
of persons with HIV/AIDS attending our clinic. This is 
probably due to the better health seeking behavior of 
women in this geo-political zone. Other factors like 
stigmatization have been reported as a major constraint 
for men. However there may be some other socio-
cultural influences which may be elucidated in further 
studies. 
The major clinical features reported by patients in this 
study were headache (100%), neck stiffness (77.8%), 
fever (72.0%), weight loss (66.7%) and personality 
changes (55.6%), vomiting (55.6%), nausea (44.4%).  
These findings are comparable with the findings in 
Malawi by Maher et al of headache (97%), neck 
stiffness (74%), fever (61%) and altered consciousness 
22
(58%).  . This frequency of symptoms were also similar 
in a study in Ethiopia by Melaku et al with headache 
(99%), fever (97.1%) vomiting (93.1%) and alteration in 
 23
mentation (39.1%) as the major symptoms . In South 
Africa, Argentina, Spain and India similar symptoms 
24,25,26,27profile was also found. . 
These high frequencies of symptoms show that most of 
our patients present with acute or subacute meningitis. 
It is also important to note that the low CD4 cell count of 
the patients could predispose them to other 
opportunistic infections that could modify their 
presentation. 
However some other studies have reported a lower 
frequency of symptoms. In Bamako, a lower frequency 
of symptoms in patients with cryptococcal meningitis 
was observed, with disorders of consciousness in 
23.6%, fever in 11.8% and signs of meningism in 64%of 
the patients. Chuck et al also found a low frequency of 
meningeal signs and symptoms (25%), vomiting (40%) 
11and encephalopathy (30%) . These findings are more 
in keeping with a chronic presentation of CM.
The median duration of meningitic symptoms was 17 
days. There was no significant difference from those 
without cryptococcal meningitis. (P=0.5800). This 
22finding is in consonance with a study in Malawi . Chuck 
et al also documented in a review of CM a duration of 2-
11
4weeks . However the time from onset to diagnosis 
ranged from days to months because cryptococcal 
meningitis can present as an acute, sub-acute or 
chronic presentation with waxing and waning 
28symptoms .
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Logistic regression showed that clinical features were not 
good predictors of the presence or absence of 
cryptococcal meningitis. Only fever and weight loss had a 
significant probability value of 0.003 and 0.031 
respectively. However these two clinical features could be 
attributable to many other opportunistic infections and HIV 
disease itself. Therefore it could be misleading to use it as 
a sole predictor of Cryptococcal meningitis in isolation 
without considering other clinical features. Studies in 
Tanzania also showed that clinical features are insensitive 
for establishing the diagnosis or prognosis of cryptococcal 
18meningitis . 
It is also important to note that fever and weight loss were 
symptoms reported by the patients which could be 
misleading depending on the patient's perception of the 
symptom.
Headache was the most prominent feature in patients with 
CM (100%), this finding was also reported in studies in 
22, 24Malawi and South Africa . Persistent headache of more 
than fourteen days was reported in 61% of patients with 
CM. In Burkina Faso, a higher percentage (75%) had 
21.persistent headache with CM  In CM several factors 
which include raised intracranial pressure, meningo-
encephalitis and systemic cytokine release could 
contribute in the pathogenesis of headache.
In patients without CM, 41% had persistent headache. 
Patients with CM are more likely to have persistent 
Nigerian Journal of Medicine,  Vol.19, No. 4 October - December 2010, ISSN 1115 2613
Frequency of Cryptococcal Meningitis: *Gomerep SS, **Idoko JA, *Ladep NG, *Ugoya SO, *Obaseki D, *Agbaji OA, *Agaba P, *Akanbi MO, *Badung BP, *Otitoloju O
2headache than patients without CM ( X =3.87, p= 
0.049).  In all 2% of patients had persistent headache 
with negative cultures, a cerebrospinal fluid cell count of 
less than 5cells/ml and without meningeal signs. This 
may group may constitute what is referred to as HIV 
headache. The pathophysiological mechanism is 
largely unknown but it is thought to be due to systemic 
cytokine release because it may sometimes herald the 
onset of systemic infection such as Pneumocystis 
29, 30.
pneumonia   
 This study found a median CD4 T cell count of 82 cells 
3 /mm in patients with Cryptococcal meningitis.  There 
was no significant difference from the patients without 
Cryptococcal meningitis. (P=0.86). Crowe and 
5colleagues  also showed that CM is always associated 
with profound immunodeficiency with CD4 T cell count 
3. 
almost invariably less than 100 cells /mm . A Study in 
Botswana by Bisson et al has shown an even lower 
3 31median CD4 count of 41 cells/mm . In Kenya a median 
3
CD4 T cell count of 17cells/mm  was found. Knudsen et 
al in Denmark found a median CD4 count of 
3 3218cells/mm  .  But the similar CD4 T cell count in 
patients without Cryptococcal meningitis may probably 
mean that our patients with HIV infection still present 
mainly at an advanced stage of AIDS. Those without 
cryptococcal meningitis may purely be a matter of non-
exposure to C. neoformans if the quality of their CD4 T 
cell is equal. These may be a subject of further research.
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